Wolters Kluwer Health announced on Thursday that information about the European meningitis B vaccine was included in its drug reference resource Lexicomp Online and Facts and Comparisons eAnswers.
Bexsero is the only vaccine proven effective against meningitis B, and is licensed for use in Europe and Australia. According to research, the virus does not respond to the four vaccines licensed for use in the United States.
Princeton University and the Centers for Disease Control and Prevention requested permission from the Food and Drug Administration to import Bexsero when eight cases of meningitis B were identified. The FDA approved the request, and the vaccine is expected to be available in December.
The University of California Santa Barbara has confirmed four additional cases.
"It was critical that we move rapidly to provide U.S. clinicians with access to clear and concise information about this life-saving vaccine" David DelToro, the vice president and general manager of Clinical Drug Information at Wolters Kluwer Health Clinical Solutions, said. "While this situation is unique the speed with which our reference solutions were updated is not. Drug information evolves rapidly and clinicians rely on these resources and our in-house clinical team to monitor the FDA current literature and pharmaceutical manufacturer announcements to provide them with reliable and current drug information."